SURMOUNT-OSA: Tirzepatide Benefits Sleep Apnea Patients With Obesity

New findings from the SURMOUNT-OSA study show that the use of tirzepatide in patients with obstructive sleep apnea (OSA) and obesity improves both OSA severity and metabolic issues. The results were presented today as a Late-Breaking Symposium at the 84th Scientific Sessions of the American Diabetes Association and simultaneously published in the New England Journal of Medicine (NEJM).


DocWire Content Partners

Powered by DocWire News

The Latest From GI Oncology Now

The Latest From Heme Today

Expert Interviews

Network Websites